Association of hypertension and hypokalemia with Cushing's syndrome caused by ectopic ACTH secretion: A series of 58 cases

Annals of the New York Academy of Sciences

Volumn 970, Issue , 2002, Pages 134-144

  Torpy, David J ^a   Mullen, Nancy ^b   Ilias, Ioannis ^c   Nieman, Lynnette K ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

11 hydroxysteroid dehydrogenase; Corticotropin; Hypertension; Hypokalemia

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTICOTROPIN; GLUCOCORTICOID; HYDROCORTISONE; POTASSIUM;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORTICOTROPIN RELEASE; CUSHING SYNDROME; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PATHOPHYSIOLOGY; SCHOOL CHILD;

EID: 0037024510     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04419.x     Document Type: Conference Paper

References (36)

1. Liddle, G.W., Givens, J.R., Nicholson, W.E. & D.P. Island. 1965. The ectopic ACTH syndrome. Cancer Res. 25: 1057-1061.
2. Nieman, L.K. 1997. Cushing's syndrome. Curr. Ther. Endocrinol. Metab. 6: 161-164.
3. Torpy, D.J., C.C. Chen, N. Mullen, et al. 1999. Lack of utility of 111-In-pentetreotide scintigraphy in localizing ectopic ACTH producing tumors: Follow-up of 18 patients. J. Clin. Endocrinol. Metab. 84: 1186-1192.
4. Jex, R.K., J.A. van Heerden, P.C. Carpenter & C.S. Grant. 1985. Ectopic ACTH syndrome: Diagnostic and therapeutic aspects. Am. J. Surg. 149: 276-282.
5. Howlett, T.A., P.L. Drury, L. Perry, et al. 1986. Diagnosis and management of ACTH dependent Cushing's syndrome: Comparison of the features of ectopic and pituitary ACTH production. Clin. Endocrinol. (Oxf.). 24: 699-713.
6. Papanicolaou, D.A., C. Tsigos, E.H. Oldfield & G.P. Chrousos. 1996. Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: Does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J. Clin. Endocrinol. Metab. 81: 2303-2306.
7. Krozowski, Z.S. & J.W. Funder. 1983. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc. Natl. Acad. Sci. USA 80: 6065-6060.
8. Funder, J.W., P.T. Pearce R. Smith & A.I. Smith. 1988. Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 242: 583-585.
9. Stewart, P.M., J.E.T. Corrie, C.H.L. Shackleton & C.R.W. Edwards. 1988. Syndrome of apparent mineralocorticoid excess: A defect in the cortisol: Cortisone shuttle. J. Clin. Invest. 82: 340-349.
10. Stewart, P.M., A.M. Wallace, R. Valentino, et al. 1987. Mineralocorticoid activity of licorice: 11β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2: 821-824.
11. Ulick, S., J.Z. Wang, J.D. Blumenfeld & T.G. Pickering. 1992. Cortisol inactivation overload: A mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J. Clin. Endocrinol. Metab. 74: 963-967.
12. Walker, B.R., J.C. Campbell, R. Fraser, et al. 1992. Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin. Endocrinol. (Oxf.). 37: 481-482.
13. Rusvai, A.N. & A.N. Fejes-Toth. 1993. A new isoform of 11β-hydroxysteroid dehydrogenase in aldosterone target cells. J. Biol. Chem. 268: 10717-10720.
14. Schambelan, M., P.E. Slaton & E.G. Biglieri. 1971. Mineralocorticoid production in hyper-adrenocortisicism. Role in pathogenesis of hypokalemic alkalosis. Am. J. Med. 51: 299-303.
15. Ritchie, C.M., B. Sheridan, R. Fraser, et al. 1990. Studies on the pathogenesis of hypertension in Cushing's disease and acromegaly. Q. J. Med. 280: 855-867.
16. Hermus, A., S. Hobma, G. Pieters, et al. 1991. Are the hypokalaemia and hypertension in Cushing's disease caused by apparent mineralocorticoid excess? Horm. Metab. Res. 23: 572-573.
17. + exchange in Cushing's syndrome reflects functional hypermineralocorticoidism. J. Hypertens. 16: 1187-1191.
18. Stewart, P.M., V.R. Walker, G. Holder, et al. 1995. 11 beta-hydroxysteroid dehydrogenase activity in Cushing's syndrome: Explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J. Clin. Endocrinol. Metab. 80: 3617-3620.
19. Ross, E.J. & D.C. Linch. 1982. Cushing's syndrome - Killing disease: Discrimination value of signs and symptoms aiding early diagnosis. Lancet 2: 646-649.
20. Etxabe, J. & J.A. Vazquez. 1994. Morbidity and mortality in Cushing's disease: An epidemiological approach. Clin. Endocrinol. (Oxf.). 40: 479-484.
21. Lindholm, J., S. Juul, J.O. Jorgensen, et al. 2001. Incidence and late prognosis of Cushing's syndrome: A population-based study. J. Clin. Endocrinol. Metab. 86: 117-123.
22. Fallo, F., A. Paoletta, F. Tona, et al. 1993. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. J. Intern. Med. 234: 595-598.
23. Ludecke, D.K. & G. Niedworok. 1985. Results of microsurgery in Cushing's disease and effect on hypertension. Cardiology 72 (Suppl.1): 91-94.
24. Fallo, F., N. Sonino, L. Barzon, et al. 1996. Effect of surgical treatment on hypertension in Cushing's syndrome. Am. J. Hypertens. 9: 77-80.
25. Suzuki, T., H. Shibata, T. Ando, et al. 2000. Risk factors associated with persistent post-operative hypertension in Cushing's syndrome. Endocr. Res. 26: 791-795.
26. Kirpichnikov, D. & J.R. Sowers. 2001. Diabetes mellitus and diabetes-associated vascular disease. Trends Endocrinol. Metab. 12: 225-230.
27. Padfield, P.L. & M.J. Stewart. 1991. Ambulatory blood pressure monitoring in secondary hypertension. J. Hypertens. 9 (Suppl 8): S69-S71.
28. Reid, I.A. 1977. Effect of angiotensin II and glucocorticoids on plasma angiotensinogen concentration in the dog. Am. J. Physiol. 232: E234-236.
29. Saruta, T., H. Suzuki, M. Handa, et al. 1986. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J. Clin. Endocrinol. Metab. 62: 275-279.
30. McKnight, J.A., D.P. Rooney, H. Whitehead & A.B. Atkinson. 1995. Blood pressure responses to phenylephrine infusions in subjects with Cushing's syndrome. J. Hum. Hypertens. 9: 855-858.
31. Tenshert, W., P. Baumgart, P. Greminger, et al. 1985. Pathogenetic aspects of hypertension in Cushing's syndrome. Cardiology 72 (Suppl 1): 84-90.
32. Radomski, M.W., R.M.J. Palmer & S. Moncada. 1990. Glucocorticoids inhibit the expression of inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. USA 87: 10043-10047.
33. Orbach, P., C.E. Wood & M. Keller-Wood. 2001. Nitric oxide reduces pressor responsiveness during ovine hypoadrenocorticism. Clin. Exp. Pharmacol. Physiol. 28: 459-462.
34. Yasunari, K., M. Kohno, K. Murakawa, et al. 1990. Glucocorticoids and atrial natriuretic factor receptors On vascular smooth muscle. Hypertension 16: 581-586.
35. Kanse, S.M., K. Takahashi, J.B. Warren, et al. 1991. Glucocrticoids induce endothelin release from vascular smooth muscle cells but not endothelial cells. Eur. J. Pharmacol. 199: 99-101.
36. 3H]dihydropyridine binding in A7r5 vascular smooth muscle cells. Am. J. Physiol. 261(1 Pt 1): C106-C114.